Veru Inc. (VERU)
After hours:
| Previous Close | 1.1600 |
| Open | 1.1400 |
| Bid | 1.4000 x 1200 |
| Ask | 1.4300 x 1200 |
| Day's Range | 1.0000 - 1.4250 |
| 52 Week Range | 0.3600 - 1.9200 |
| Volume | |
| Avg. Volume | 2,478,470 |
| Market Cap | 207.861M |
| Beta (5Y Monthly) | -0.20 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7000 |
| Earnings Date | May 09, 2024 - May 13, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Apr 28, 2014 |
| 1y Target Est | 2.75 |
ZacksWhat Makes Veru (VERU) a New Buy Stock
Veru (VERU) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
GlobeNewswireVeru Announces Date of 2024 Annual Meeting of Shareholders
--2023 Form 10-K/A and Q1 2024 Form 10-Q filed today-- --2024 Annual Meeting of Shareholders will be June 18, 2024 -- MIAMI, FL, April 01, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the Company has now filed both an amendment to its Annual Report on Form 10-K/A f
- GlobeNewswire
Veru Reschedules Annual Meeting of Shareholders
--Restated historical financial statements expected to be filed no later than April 15, 2024-- --2024 Annual Meeting of Shareholders to follow financial statements filings-- MIAMI, FL, March 22, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that it is rescheduling its 20
